Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329651 | 1.00 | USP30 (0.45) | USP30GPR119SMN1; SMN2USP2ATM | |
| SCHEMBL3329274 | 1.00 | USP30 (0.45) | USP30GPR119SMN1; SMN2USP2ATM | |
| SCHEMBL3185439 | 1.00 | USP30 (0.45) | USP30GPR119SMN1; SMN2USP2ATM | |
| SCHEMBL5705724 | 0.88 | USP2 (0.41) | GPR119SMN1; SMN2USP2JAK2JAK1 | |
| SCHEMBL970289 | 0.87 | STS (0.44) | USP30SMN1; SMN2 | |
| SCHEMBL5289397 | 0.87 | PDE4B (0.40) | USP30GPR119SMN1; SMN2USP2KDM4E | |
| SCHEMBL970288 | 0.87 | STS (0.44) | USP30SMN1; SMN2 | |
| SCHEMBL3329066 | 0.87 | GPR119 (0.44) | USP30GPR119SMN1; SMN2USP2HPGDS | |
| SCHEMBL3327776 | 0.87 | GPR119 (0.44) | USP30GPR119SMN1; SMN2USP2HPGDS | |
| SCHEMBL5289408 | 0.87 | PDE4B (0.40) | USP30GPR119SMN1; SMN2USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | USP30 3956/4885GPR119 1216/4885SMN1; SMN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.